Quick Answer
IOVANCE BIOTHERAPEUTICS, INC. reported Research And Development Expense of $300.27 million for the year ending 2025.
- IOVANCE BIOTHERAPEUTICS, INC. showed an increase of +8.7% in Research And Development Expense from 2024 to 2025.
- This data is from IOVANCE BIOTHERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: $270.0 thousand | Q2 2013: $250.0 thousand | Q3 2013: $250.0 thousand | Q1 2014: $302.7 thousand | Q2 2014: $494.0 thousand | Q3 2014: $354.0 thousand | Q1 2015: $2.40 million | Q2 2015: $4.06 million | Q3 2015: $4.96 million | Q1 2016: $4.19 million | Q2 2016: $4.46 million | Q3 2016: $8.48 million | Q1 2017: $15.59 million | Q2 2017: $18.65 million | Q3 2017: $16.68 million | Q1 2018: $19.91 million | Q2 2018: $24.55 million | Q3 2018: $27.95 million | Q1 2019: $30.91 million | Q2 2019: $39.30 million | Q3 2019: $41.58 million | Q1 2020: $56.95 million | Q2 2020: $49.27 million | Q3 2020: $43.05 million | Q1 2021: $55.95 million | Q2 2021: $62.12 million | Q3 2021: $65.36 million | Q1 2022: $68.30 million | Q2 2022: $73.41 million | Q3 2022: $72.50 million | Q1 2023: $82.73 million | Q2 2023: $86.35 million | Q3 2023: $87.53 million | Q1 2024: $79.78 million | Q2 2024: $62.08 million | Q3 2024: $67.04 million | Q1 2025: $76.88 million | Q2 2025: $79.36 million | Q3 2025: $75.17 million.
- Historical annual values: Fiscal year 2025: $300.27 million | Fiscal year 2024: $276.23 million | Fiscal year 2023: $333.19 million | Fiscal year 2022: $294.78 million | Fiscal year 2021: $259.04 million | Fiscal year 2020: $201.73 million | Fiscal year 2019: $166.02 million | Fiscal year 2018: $99.83 million | Fiscal year 2017: $71.62 million | Fiscal year 2016: $26.94 million | Fiscal year 2015: $15.47 million | Fiscal year 2014: $3.85 million | Fiscal year 2013: $2.15 million | Fiscal year 2012: $1.66 million | Fiscal year 2011: $1.76 million | Fiscal year 2010: $171.5 thousand | Fiscal year 2009: $0.00.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: